Peroxisome proliferator‑activated receptor γ2 Pro12Ala (rs1801282) polymorphism and breast cancer susceptibility: A meta‑analysis

Mao,Qunxia; Guo,Huilin; Gao,Linggen; Wang,Hongwei; Ma,Xu

doi:10.3892/mmr.2013.1735

Peroxisome proliferator‑activated receptor γ2 Pro12Ala (rs1801282) polymorphism and breast cancer susceptibility: A meta‑analysis

Authors:
- Qunxia Mao
- Huilin Guo
- Linggen Gao
- Hongwei Wang
- Xu Ma
View Affiliations

Affiliations: Research Centre of Social Medicine, National Research Institute for Family Planning, Beijing, P.R. China, Department of Oncology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, P.R. China, Department of Geriatric Cardiology, General Hospital of Chinese People's Liberation Army, Beijing, P.R. China, Department of Safety Engineering, China Institute of Industrial Relations, Beijing, P.R. China, National Research Institute for Family Planning, Beijing, P.R. China
Published online on: October 16, 2013 https://doi.org/10.3892/mmr.2013.1735
Pages: 1773-1778

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Several studies have investigated the correlation between the peroxisome proliferator‑activated receptor γ2 (PPAR‑γ2) Pro12Ala (rs1801282) polymorphism and the risk of breast cancer, with inconsistent results. For this reason, a meta‑analysis was conducted to identify the potential correlation after pooling data from eligible case‑control studies. Search strategies were conducted in PubMed, EMBASE and the COCHRANE Library in English and from VIP, CNKI and Sinomed in Chinese (all the papers were published before November 11, 2012) using appropriate terms. A total of 2,279 cases and 2,360 controls from four related case‑control studies were included in this meta‑analysis. According to the three eligible populations, the odds ratios (ORs) and 95% confidence intervals (CIs) on the risk of breast cancer for the CG versus CC and GG versus CC genotypes and the G versus C allele were 0.84 and 0.72‑0.98, 0.92 and 0.32‑2.61, and 0.98 and 0.84‑1.13, respectively. The OR and 95% CI for CG+GG versus CC from the four study populations were 0.85 and 0.73‑0.98, respectively. This meta‑analysis supported the fact that the G allele of PPAR‑γ2 Pro12Ala (rs1801282) modestly affects the risk of breast cancer. Nevertheless, further studies are required to enrich the evidence of this correlation.

View Figures

View References

1	World Health Organization. Breast cancer: prevention and control. www.who.int/cancer/detection/breastcancer/en/https://www.who.int/cancer/detection/breastcancer/en/. Accessed Jan 6, 2013
2	World health statistics 2008: Part 1: Ten highlights in health statistics. http://www.who.int/whosis/whostat/EN_WHS08_Part1.pdf. Accessed Jan 6, 2013
3	The global burden of disease: 2004 update. www.who.int/healthinfo/global_burden_disease/2004_report_update/en/https://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/. Accessed Jan 6, 2013
4	Guo H, Ming J, Liu C, et al: A common polymorphism near the ESR1 gene is associated with risk of breast cancer: evidence from a case-control study and a meta-analysis. PLoS One. 7:e524452012. View Article : Google Scholar : PubMed/NCBI
5	Li LW and Xu L: Menopausal status modifies breast cancer risk associated with ESR1 PvuII and XbaI polymorphisms in Asian women: a HuGE review and meta-analysis. Asian Pac J Cancer Prev. 13:5105–5111. 2012. View Article : Google Scholar : PubMed/NCBI
6	Yu L and Chen J: Association of MTHFR Ala222Val (rs1801133) polymorphism and breast cancer susceptibility: An update meta-analysis based on 51 research studies. Diagn Pathol. 7:1712012. View Article : Google Scholar : PubMed/NCBI
7	Wei G, Wang Y, Zhang P, Lu J and Mao JH: Evaluating the prognostic significance of FBXW7 expression level in human breast cancer by a meta-analysis of transcriptional profiles. J Cancer Sci Ther. 4:299–305. 2012.PubMed/NCBI
8	Mao Q, Gao L, Wang H, Wang Q and Zhang T: The alcohol dehydrogenase 1C(rs698) genotype and breast cancer: A meta-analysis. Asia Pac J Public Health. May 31–2012.(Epub ahead of print).
9	Wu MH, Chu CH, Chou YC, Chou WY, Yang T, Hsu GC, Yu CP, Yu JC and Sun CA: Joint effect of peroxisome proliferator-activated receptor γ genetic polymorphisms and estrogen-related risk factors on breast cancer risk: results from a case-control study in Taiwan. Breast Cancer Res Treat. 127:777–784. 2011.
10	Cho MC, Lee K, Paik SG and Yoon DY: Peroxisome proliferators-activated receptor (PPAR) modulators and metabolic disorders. PPAR Res. 2008:6791372008.PubMed/NCBI
11	Memisoglu A, Hankinson SE, Manson JE, Colditz GA and Hunter DJ: Lack of association of the codon 12 polymorphism of the peroxisome proliferator-activated receptor gamma gene with breast cancer and body mass. Pharmacogenetics. 12:597–603. 2002. View Article : Google Scholar : PubMed/NCBI
12	Dallongeville J, Iribarren C, Ferrières J, et al: Peroxisome proliferator-activated receptor gamma polymorphisms and coronary heart disease. PPAR Res. 2009:5437462009. View Article : Google Scholar : PubMed/NCBI
13	He W: PPARγ2 polymorphism and human health. PPAR Res. 2009:8495382009.
14	Spiegelman BM: PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes. 47:507–514. 1998. View Article : Google Scholar : PubMed/NCBI
15	Ho JS, Germer S, Tam CH, et al: Association of the PPARG Pro12Ala polymorphism with type 2 diabetes and incident coronary heart disease in a Hong Kong Chinese population. Diabetes Res Clin Pract. 97:483–491. 2012. View Article : Google Scholar : PubMed/NCBI
16	Prakash J, Srivastava N, Awasthi S, et al: Association of PPAR-γ gene polymorphisms with obesity and obesity-associated phenotypes in North Indian population. Am J Hum Biol. 24:454–459. 2012.
17	Alsaleh A, Frost GS, Griffin BA, et al; RISCK Study Investigators. PPARγ2 gene Pro12Ala and PPARα gene Leu162Val single nucleotide polymorphisms interact with dietary intake of fat in determination of plasma lipid concentrations. J Nutrigenet Nutrigenomics. 4:354–366. 2011.
18	Poliska S, Penyige A, Lakatos PL, et al; Hungarian IBD Study Group. Association of peroxisome proliferator-activated receptor gamma polymorphisms with inflammatory bowel disease in a Hungarian cohort. Inflamm Bowel Dis. 18:472–479. 2012. View Article : Google Scholar : PubMed/NCBI
19	Justenhoven C, Hamann U, Schubert F, et al: Breast cancer: a candidate gene approach across the estrogen metabolic pathway. Breast Cancer Res Treat. 108:137–149. 2008. View Article : Google Scholar : PubMed/NCBI
20	Wang Y, McCullough ML, Stevens VL, et al: Nested case-control study of energy regulation candidate gene single nucleotide polymorphisms and breast cancer. Anticancer Res. 27:589–593. 2007.PubMed/NCBI
21	Petersen RK, Larsen SB, Jensen DM, et al: PPARgamma-PGC-1alpha activity is determinant of alcohol related breast cancer. Cancer Lett. 315:59–68. 2012. View Article : Google Scholar : PubMed/NCBI
22	Kim KZ, Shin A, Lee YS, Kim SY, Kim Y and Lee ES: Polymorphisms in adiposity-related genes are associated with age at menarche and menopause in breast cancer patients and healthy women. Hum Reprod. 27:2193–2200. 2012. View Article : Google Scholar : PubMed/NCBI
23	Wells GA, Shea B, O’Connell D, et al: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available from: URL: www.ohri.ca/programs/clinical_epidemiology/oxford.asphttps://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed Nov 26, 2011
24	Wirtenberger M, Tchatchou S, Hemminki K, et al: Associations of genetic variants in the estrogen receptor coactivators PPARGC1A, PPARGC1B and EP300 with familial breast cancer. Carcinogenesis. 27:2201–2208. 2006. View Article : Google Scholar : PubMed/NCBI
25	Li Y, Li Y, Wedrén S, et al: Genetic variation of ESR1 and its co-activator PPARGC1B is synergistic in augmenting the risk of estrogen receptor-positive breast cancer. Breast Cancer Res. 13:R102011. View Article : Google Scholar : PubMed/NCBI
26	Paynter RA, Hankinson SE, Colditz GA, Hunter DJ and De Vivo I: No evidence of a role for PPARgamma Pro12Ala polymorphism in endometrial cancer susceptibility. Pharmacogenetics. 14:851–856. 2004. View Article : Google Scholar : PubMed/NCBI
27	Posch MG, Zang C, Mueller W, Lass U, von Deimling A and Elstner E: Somatic mutations in peroxisome proliferator-activated receptor-gamma are rare events in human cancer cells. Med Sci Monit. 10:BR250–BR254. 2004.PubMed/NCBI
28	Ondrey F: Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention. Clin Cancer Res. 15:2–8. 2009. View Article : Google Scholar
29	Gallicchio L, McSorley MA, Newschaffer CJ, et al: Body mass, polymorphisms in obesity-related genes, and the risk of developing breast cancer among women with benign breast disease. Cancer Detect Prev. 31:95–101. 2007. View Article : Google Scholar : PubMed/NCBI
30	Vogel U, Christensen J, Nexø BA, Wallin H, Friis S and Tjønneland A: Peroxisome profilerator-activated [corrected] receptor-gamma2 [corrected] Pro12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes. Carcinogenesis. 28:427–434. 2007.
31	Lee E, Hsu C, Van den Berg D, et al: Genetic variation in peroxisome proliferator-activated receptor gamma, soy, and mammographic density in Singapore Chinese women. Cancer Epidemiol Biomarkers Prev. 21:635–644. 2012. View Article : Google Scholar : PubMed/NCBI